Florida Pharmacy Shut Down as Public Health Menace
Published Date: 1/23/2025
Notice
Summary
Xubex Community Pharmacy in Florida lost its DEA registration because it was seen as a danger to public health. The pharmacy didn’t ask for a hearing to defend itself, so the suspension became final. This means Xubex can’t legally handle controlled substances anymore, effective immediately, impacting their business and customers.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Revokes Xubex Pharmacy Registration
The DEA revoked Xubex Community Pharmacy's Certificate of Registration No. FX3643081 and denied any pending applications for renewal, modification, or additional registration in Florida. The final Order revocation is effective February 24, 2025, after an earlier OSC/ISO and immediate suspension issued May 29, 2024.
Customers Lose Access to Controlled Drugs
Because Xubex Community Pharmacy can no longer handle controlled substances, customers who got controlled drugs there can no longer obtain them from that pharmacy. The Agency found that on November 30, 2023 Xubex dispensed ten oxycodone tablets for $260 without a prescription and on December 19, 2023 it dispensed two hydromorphone tablets for $50; the pharmacy did not request a hearing and the revocation is effective February 24, 2025.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-01536 — Neumann's Pharmacy, LLC; Decision and Order
Neumann's Pharmacy in Louisiana lost its DEA registration because it didn’t meet important pharmacy rules that keep the public safe. After a full hearing and review, the government decided to revoke their license, meaning they can’t legally handle controlled medicines anymore. This change takes effect soon and could impact the pharmacy’s business and customers relying on their services.
Next: 2025-01540 — Notice of Determination Pursuant to Section 301: China's Targeting of the Maritime, Logistics, and Shipbuilding Sectors for Dominance
The U.S. says China is trying to take over key industries like shipping, logistics, and shipbuilding unfairly. Because of this, the U.S. is stepping up with new rules and possible tariffs to protect American businesses. These changes could affect companies involved in these sectors soon and might impact trade costs.